Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report) was the target of a significant decline in short interest in May. As of May 31st, there was short interest totalling 166,800 shares, a decline of 44.4% from the May 15th total of 300,100 shares. Approximately 0.0% of the company's stock are sold short. Based on an average daily volume of 766,700 shares, the days-to-cover ratio is currently 0.2 days.
Reckitt Benckiser Group Trading Down 1.8%
RBGLY stock traded down $0.25 during trading hours on Friday, reaching $13.89. The stock had a trading volume of 245,435 shares, compared to its average volume of 382,860. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.47 and a current ratio of 0.69. The stock has a 50-day simple moving average of $13.18 and a 200 day simple moving average of $12.93. Reckitt Benckiser Group has a fifty-two week low of $10.43 and a fifty-two week high of $14.15.
Analyst Ratings Changes
A number of analysts have recently commented on RBGLY shares. Sanford C. Bernstein raised shares of Reckitt Benckiser Group from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Royal Bank of Canada reissued an "outperform" rating on shares of Reckitt Benckiser Group in a research report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, Reckitt Benckiser Group presently has an average rating of "Buy".
Read Our Latest Analysis on Reckitt Benckiser Group
Reckitt Benckiser Group Company Profile
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Further Reading
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
